Drug Search Results
More Filters [+]

CLE-400

Alternative Names: CLE-400, CLE400, CLE 400
Latest Update: 2024-12-24
Latest Update Note: Clinical Trial Update

Product Description

Clexio is developing CLE-400, a topical gel formulation containing a non-opioid, non-steroid, analgesic compound, to treat patients suffering from peripheral neuropathic pain. CLE-400 is a new investigational drug that has not been approved for commercial distribution. (Sourced from: https://www.clexio.com/pipeline/cle-400-pain/)

Mechanisms of Action: ADRA2 Agonist

Novel Mechanism: Yes

Modality: N/A

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Clexio Biosciences
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for CLE-400

Countries in Clinic: United States

Active Clinical Trial Count: 1

Highest Development Phases

Phase 2: Back Pain|Chronic Pain|Pruritus

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

CLE400-NP-201

P2

Completed

Pruritus|Chronic Pain|Back Pain

2024-11-06

Recent News Events

Date

Type

Title